Clinical management of myeloma--state of the art.
In the last decade, advances in our understanding of the biology of myeloma have led to new treatment approaches that have resulted in unprecedented improvements in survival outcomes. These gains can be attributed in part to the introduction of three new active agents for the treatment of myeloma: thalidomide, lenalidomide, and bortezomib. With these treatments, however, have come new questions regarding the optimal approach to therapy, expected outcomes, and safety issues. In the articles included in this supplement, experts at the forefront of myeloma research provide insight into the management of patients with myeloma, and the current issues that clinicians face today regarding the best use of these agents.
Harousseau
Jean-Luc
JL
Centre René Gauducheau, Nantes St Herblain, France. jl-harousseau@nantes.fnclcc.fr
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide